Telix Pharmaceuticals (TLPPF) Projected to Post Earnings on Friday

Telix Pharmaceuticals (OTCMKTS:TLPPF) is anticipated to announce its results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of $0.0328 per share and revenue of $322.8750 million for the quarter.

Telix Pharmaceuticals Price Performance

Shares of Telix Pharmaceuticals stock opened at $6.61 on Friday. Telix Pharmaceuticals has a 52-week low of $6.15 and a 52-week high of $24.85. The company’s fifty day moving average price is $7.77 and its two-hundred day moving average price is $9.41.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.